Obinutuzumab: Uses and Availability in India

Both attach to the same target, CD20, but they hold on to it differently. Rituximab is a type I antibody. Obinutuzumab is a type II antibody, humanised and glycoengineered so that immune cells recognise it more strongly. The result is more direct B-cell death, a fixed dose instead of a body-size dose, and more infusion reactions on the first day.

The two are usually described as first-generation and second-generation, which makes it sound as though the newer one simply replaces the older one. That is the part worth slowing down on, because it is not what the evidence shows. Obinutuzumab was designed to bind CD20 in a different orientation, and its sugar coating was engineered so that the body’s immune cells attach to it more firmly. That changes the mix of mechanisms: more killing by immune cells, more direct death of the B cell itself, and less killing through the complement system that rituximab leans on. Different, and in some diseases better at controlling disease — but not automatically the right antibody for a given patient.

The practical differences show up on the day-care chair and on the bill, not in the biology.

What the trials actually compared. In previously untreated chronic lymphocytic leukaemia in older patients with other illnesses, a randomised trial compared obinutuzumab plus chlorambucil against rituximab plus chlorambucil, and reported longer disease control and deeper remissions with obinutuzumab, alongside more infusion reactions and more low neutrophil counts. In previously untreated follicular lymphoma, a second randomised trial compared obinutuzumab plus chemotherapy against rituximab plus chemotherapy, and reported a longer time before the lymphoma progressed — with more side effects in the obinutuzumab group. Neither result is a statement about how long any particular patient will live, and neither should be read as one.

The counter-example matters just as much. In diffuse large B-cell lymphoma, the commonest aggressive lymphoma, randomised trials of obinutuzumab with CHOP chemotherapy did not show an advantage over rituximab with CHOP. R-CHOP remains the standard regimen there. A newer antibody is not a better antibody in every disease, and that is a genuine finding rather than a caution. For the older molecule’s full picture, see Rituximab: uses, cost and side effects.

Mainly two: chronic lymphocytic leukaemia and follicular lymphoma. Both are B-cell cancers that carry CD20 on the cell surface. It is not the standard antibody for diffuse large B-cell lymphoma. It is not used in Hodgkin lymphoma, myeloma or T-cell lymphoma, and it has no role in solid tumours such as breast, lung or colorectal cancer.

As with every anti-CD20 antibody, the deciding line is not the diagnosis word but the immunohistochemistry on the biopsy or the flow cytometry on the marrow. If CD20 is not present, the antibody has nothing to attach to, and price and availability become irrelevant questions.

An Indian regulatory update worth knowing. In April 2026, Indian financial and pharmaceutical press reported that the CDSCO approved acalabrutinib tablets in combination with venetoclax, with or without obinutuzumab, for previously untreated chronic lymphocytic leukaemia. That matters here for one reason: in current leukaemia practice this antibody increasingly appears as one component of a fixed-duration combination rather than as an open-ended treatment on its own.

Outside cancer care, the same molecule was approved by the United States FDA in October 2025 for lupus nephritis, a kidney complication of lupus. Whether that indication is separately approved in India is a distinct regulatory question, and it is not covered by the 2015 oncology permission described below.

Yes — it is approved and marketed here, though it is used sparingly. The CDSCO list of drugs imported and marketed in India records an import-and-market permission for obinutuzumab to Roche Products (India) Pvt Ltd dated 2 January 2015, in combination with chlorambucil for previously untreated chronic lymphocytic leukaemia. Roche India publishes local prescribing information for it under the brand Gazyva.

That is the national picture. Three things follow from it, and they are the ones families actually run into.

• Approval is not the same as stock. Obinutuzumab is a cold-chain biological stored between 2 °C and 8 °C, and it is expensive to hold on a shelf. Many hospital pharmacies order it against a confirmed prescription rather than keeping it in stock, which adds days. Ask the treating unit how it is sourced, and how long the first dose takes to arrange, before the schedule is fixed.
• It is used sparingly in India. Published health-policy work comparing access to lymphoma and leukaemia medicines in India and the United States records exactly this — the molecule is available, but its cost limits how often it is chosen. That is a description of Indian practice, not a judgement on it.
• There is no Indian biosimilar as of August 2026. Rituximab’s price fell because Indian biosimilars arrived from 2007 onwards. Nothing equivalent has happened for obinutuzumab; published patent analyses place its core patents in the early 2030s. So there is no cheaper brand of this exact molecule to ask a pharmacy for.

If a supplier offers this molecule far below published listings, or without a prescription and a documented cold chain, that is a reason to stop and verify rather than to proceed — see cold-chain storage and what can go wrong.

Most cancer patients, including most people who arrive here after reading about immunotherapy. Obinutuzumab acts only where CD20 is present on the cancer cell. If the biopsy or marrow report does not show CD20, this antibody has no target, and neither its newness nor its price makes it an option.

Concretely, it is not a treatment for solid tumours — breast, lung, colorectal, prostate, head and neck, cervical or ovarian cancer. It is not used in Hodgkin lymphoma, in myeloma, or in T-cell lymphoma. And it is not a checkpoint inhibitor: obinutuzumab and medicines such as pembrolizumab or nivolumab work by different mechanisms in different diseases, and they are not alternatives to one another.

It is also not the antibody of choice in diffuse large B-cell lymphoma, even though that lymphoma is CD20-positive. Randomised trials of obinutuzumab with CHOP chemotherapy did not show an advantage over rituximab with CHOP, so rituximab remains standard there. Asking for the newer antibody in that setting means paying considerably more without evidence of doing better.

Within CD20-positive leukaemia and follicular lymphoma it still is not for everyone. It is not given during an active severe infection, or to anyone who has had a severe reaction to it before. Everyone needs hepatitis B screening first, because anti-CD20 antibodies can reactivate a dormant hepatitis B infection. Existing heart or lung disease is weighed carefully before the first infusion, since a significant reaction places real strain on both. It is not established for use under 18 years of age. Pregnancy and breastfeeding are avoided, and contraception is advised during treatment and for a defined period after the last dose — the labelled interval is longer than most people expect, so it needs an explicit conversation before cycle one, not after it.

One question is always reasonable: whether the treatment plan needs this antibody at all, or whether a well-established alternative fits the diagnosis equally well. One question is not useful: asking to swap one anti-CD20 antibody for another to save money. They are not interchangeable, and the choice belongs to the treating haematologist.

As a slow drip into a vein, in a day-care unit, at a fixed 1000 mg dose. In chronic lymphocytic leukaemia the very first 1000 mg is deliberately split across two days — 100 mg on day 1 and 900 mg on day 2 — because infusion reactions cluster in that first exposure. Later infusions are usually far less eventful.

The sequence below is the general pattern. The exact schedule depends on the disease and the regimen, and is set by the treating team.

1. Before the first dose. Blood counts, kidney and liver tests, and hepatitis B screening. The hepatitis B test is not optional — see the monitoring section below.
2. Premedication. A corticosteroid, paracetamol and an antihistamine, given ahead of the infusion. This is what keeps most first-day reactions manageable.
3. Tumour lysis precautions where the disease burden is high. Extra fluids and a uric-acid-lowering medicine, started before the first dose in leukaemia with a high cell count.
4. Day 1: a small, slow dose. Only 100 mg in chronic lymphocytic leukaemia, run slowly, with close observation of blood pressure, pulse and temperature.
5. Day 2: the rest of the first dose. The remaining 900 mg, if day 1 was tolerated.
6. Days 8 and 15 of the first cycle. A full 1000 mg on each, completing the loading phase.
7. Later cycles. A single 1000 mg infusion on day 1 of each cycle. In follicular lymphoma, maintenance dosing every two months may follow, for a defined period.
8. Home the same day. This is day-care treatment. Admission is needed only if something else in the regimen calls for it.

The fixed dose is worth noticing. Unlike rituximab, obinutuzumab is not calculated from height and weight — every adult receives the same milligrams. That simplifies the arithmetic, but it removes the small saving a smaller patient would otherwise see, and it is why the vial count for a course is the same for everyone.

Indicatively around ₹3.4 lakh for one 1000 mg vial as of August 2026, based on published listings on Indian pharmacy platforms. Discounted retail listings start near ₹2.95 lakh, and one large platform still shows an older maximum retail price close to ₹4 lakh. Because there is no Indian biosimilar, there is no cheaper version of this molecule.

The drug is one line of the bill, not the bill. Day-care charges, nursing and infusion time, premedication, the chemotherapy or targeted tablets given alongside, pre-cycle blood tests and response-assessment imaging are all billed separately. Two hospitals can quote different totals while using the same vial. An itemised estimate — drug, day care, monitoring, supportive care — is the only way to compare two plans honestly.

Assistance programmes exist and are advertised publicly. Indian pharmacy platforms carry manufacturer patient support and patient assistance programme information for this medicine, and one platform states that it administers such a programme. Eligibility is decided by the programme sponsor against its own criteria, not by any treating centre, so it is worth asking the prescribing haematologist to make that referral early rather than after the first cycle has been paid for.

On schemes and insurance. Government scheme ceilings such as Aarogyasri are written against protocols, not brands, and a high-cost antibody may sit outside the package for a given procedure. Private insurance sub-limits for injectable oncology medicines differ policy to policy. Confirm the applicable ceiling in writing before cycle one. For how prices in this category actually move over time, and which molecules have Indian biosimilars, see which immunotherapy medicines have Indian biosimilars today.

Mainly infection risk, blood counts and the liver. The antibody clears normal B cells along with the abnormal ones, so antibody levels can stay low for months after treatment ends. Neutrophil counts can fall late. Hepatitis B can reactivate. None of this argues against the medicine — it is the reason for the monitoring schedule around it.

• Hepatitis B reactivation. Screening for HBsAg and anti-HBc before the first dose is a labelled requirement for anti-CD20 antibodies and is built into NCCN and ASCO guidance. A past infection that appears cleared can still reactivate, which is why both tests are done and why antiviral cover is started where indicated.
• Neutropenia, including late-onset. The count can drop weeks or months after a dose. Any fever needs an urgent blood count the same day.
• Low immunoglobulins and repeat infections. Antibody levels can remain low long after the last cycle. A minority of patients need immunoglobulin replacement.
• Tumour lysis syndrome. Highest risk at the first dose in leukaemia with a high cell count. Prevented with fluids and uric-acid-lowering medicine, and detected on blood tests rather than by symptoms.
• Vaccination timing. Live vaccines are avoided during and for a period after treatment, and the response to any vaccine may be poor for months. Where there is time, vaccination is completed before starting.
• Progressive multifocal leukoencephalopathy. Rare, but a labelled warning. New confusion, weakness on one side, or changes in vision or speech need urgent review.
• Pregnancy and contraception. Avoided in pregnancy and breastfeeding, with contraception advised during treatment and for a defined period after the last dose. Fertility planning belongs in the conversation before cycle one.

One honest limitation: because obinutuzumab has been in use since 2013 rather than the late 1990s, its very-long-term safety record is shorter than rituximab’s. Most of what is known about anti-CD20 antibodies decades out comes from the older molecule. That is a statement about the maturity of the evidence, not a warning signal.

Obinutuzumab sits inside a wider family of antibody medicines used in blood cancers — some targeting a marker directly, some carrying chemotherapy to it, some pulling T cells towards it. These pages cover the neighbours.

• Polatuzumab Vedotin: Uses and Availability in India — an antibody-drug conjugate used in aggressive B-cell lymphoma, the disease where obinutuzumab is not the standard.
• Teclistamab, Talquetamab and Myeloma Bispecifics — antibodies that engage T cells rather than flagging a cell for destruction.
• Isatuximab and Elotuzumab in Myeloma — the same antibody idea against a different marker, in a disease where CD20 antibodies have no role.
• Rituximab: Uses, Cost and Side Effects — the older anti-CD20 antibody this page is measured against.
• Immunotherapy Medicines Explained — the index of antibodies, checkpoint inhibitors and biosimilars.
• Immunotherapy at a glance — what this family of treatments does, and what it does not.

Editorial information about a prescription-only medicine — not an offer, a price list, or a recommendation to use any named product, and no comparative quality claim between manufacturers. Clinical statements follow product labelling and published NCCN, ASCO and ESMO patient-education guidance; regulatory statements follow the CDSCO record of drugs imported and marketed in India and the manufacturer’s published Indian prescribing information. All pricing is indicative and dated to August 2026. Whether obinutuzumab applies to a particular patient, and in which regimen, is a decision for the treating haematologist or medical oncologist.